Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-02, Vol.17 (1), p.e63-e64
Main Authors: Facon, Thierry, Dimopoulos, Meletios Athanasios, Dispenzieri, Angela, Catalano, John, Belch, Andrew R, Cavo, Michele
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2017.03.116